Considering that over half of American adults believe Elvis is alive, I think the small percentage who may slightly overreact to the kind of presentation that 23andme gives of these kinds of results is a complete non-issue.
http://www.bmj.com/content/333/7562/284
For screening tests where the problem being screened for is rare, most results will be false positives, but the result is not intuitive.
Unfortunately for us, the FDA is on a quest for "safety"; the agency does not try to help the citizenry live longer or happier.
23andMe isn't even doing that.
The 23andme product explains explicitly how it should be used by a physician, and there are all kinds of warnings and checkboxes before the user is shown any data that falls into the area of overlap.
('carbocation has already expressed some tacit support for FDA's action, but I'm not qualified to interpret it in the context of this particular subthread).
Generally, for diagnostic tools, drugs, etc., it is not enough that the product labelling explains how it should be used, but it is required to demonstrate to the FDA that there is evidence that it works as marketed when used according to those directions. The FDA Warning Letter specifically calls out 23andMe's failure to either identify existing approved products on the market to which the product is equivalent (which wouldn't reduce the requirements for proving this) or to meet the requirements for demonstrating the effectiveness of their offering as a new product without existing, approved equivalents.
There are at least three different products in the space and to claim similarity would be to likely invite over-regulation:
- "full scan" companies, that do a full genetic scan and do not limit the scan to SNPs
- personal genomics companies that focus on SNPs
- medial diagnostics like the MSAFP test
I don't know enough about 23andMe's operations and those of what appear from the outside to be generally similar services to answer that. Assuming that they really are an innovative service, they would need to conduct and provide the studies supporting the validity of their innovative service.
Any doctor educated in the past two decades
is well versed in genetic testing
I'm not sure what definition of "well versed in genetic testing" you had in mind but this is untrue for most or all reasonable definitions. any doctor specializing in areas where genetic testing
is a frequently used aspect of planning/diagnosis
(such as OB/GYN) will be highly familiar even if trained long ago.
Also an overstatement. The trouble is that "genetic testing" is a large and complex field. Are you referring to a single-gene test for a well-known and well-characterized disease? Or whole exome sequencing? Because in the coming years doctors will come into contact with both. In general these tests will require specialist interpretation; not general physicians or OB/GYNs.If physicians are forced to waste huge amounts of time and effort to console an influx of patients who have been wrongly told they have some terrible disease, this is going to reduce the amount of time they have available to work with patients with actual terrible diseases.
If other medical device/diagnostic makers have to comply with the law, so should 23andme.
If we really cared about public health we'd have a drastically different system.
In any case I think it's hard to make a persuasive argument that if the members of the public were only kept more naive about their own health risks, public health would improve.
This could result in a large number of unnecessary follow-up BRCA tests which could potentially increase the waiting time for test results or unduly raise costs for lots of patients. Not to mention the stress of feeling like you may be suffering from a potentially expensive and life-threatening illness.
So: totally reasonable.